Table of contents
From the editors
p1 | doi:10.1038/nri2013
Research Highlights
Immune tolerance: Arming the front line with TLR9
p2 | doi:10.1038/nri2006
HIV: Breaching the barrier
p3 | doi:10.1038/nri2001
In brief
T cells | Immunotherapy | Autoimmunity
p3 | doi:10.1038/nri2010
Antibody responses: Neighbourly help in the gut
p4 | doi:10.1038/nri2002
T cells: A stimulating collaboration
p4 | doi:10.1038/nri2008
Dendritic cells: Terminal differentiation of plasmacytoid dendritic cells
p4 | doi:10.1038/nri2009
In brief
Lymphocyte migration | Natural killer cells | T-cell migration
p5 | doi:10.1038/nri2011
T Helper cells: TH17 cells linked to bone destruction
p6 | doi:10.1038/nri2005
T-cell activation: Which signal to respond to?
p6 | doi:10.1038/nri2007
Autoimmunity: Osteopontin: role in MS relapses
p7 | doi:10.1038/nri2004
Immunodeficiency: Beyond expectation
p8 | doi:10.1038/nri2003
In the news
Maps for malaria
p8 | doi:10.1038/nri2012
Reviews
T-cell regulation: with complements from innate immunity
Claudia Kemper and John P. Atkinson
p9 | doi:10.1038/nri1994
The complement system is known to be a main part of both innate and antibody-mediated immunity. Here the emerging role of complement in the regulation of the initiation, effector and contraction phases of the T-cell response is discussed, and new perspectives in this area are revealed.
Steady-state and inflammatory dendritic-cell development
Ken Shortman and Shalin H. Naik
p19 | doi:10.1038/nri1996
This Review integrates information from in vitro and in vivo models of dendritic-cell (DC) development to provide an emerging, but still fragmented, picture of the pathways and precursor cells that lead to the different DC subtypes in the steady state and during inflammation.
Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation
Sanjeev Mariathasan and Denise M. Monack
p31 | doi:10.1038/nri1997
The inflammasome is a cytosolic, multiprotein platform that regulates post-translational cytokine processing and is essential for innate immune defence. What lessons can be learned from the most recent studies on inflammasome activation in response to bacterial pathogens and tissue damage?
Article series: Tumour immunology
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Hua Yu, Marcin Kortylewski and Drew Pardoll
p41 | doi:10.1038/nri1995
The involvement of STAT3 in both oncogenic and immunosuppressive signalling pathways provides a molecular mechanism for the bidirectional communication between malignant cells and immune cells, and makes STAT3 an important target for tumour immunotherapy.
Regulation of immune tolerance by anti-inflammatory neuropeptides
Elena Gonzalez-Rey, Alejo Chorny and Mario Delgado
p52 | doi:10.1038/nri1984
Some neuropeptides have been shown to have anti-inflammatory properties and to participate in maintaining immune tolerance. Here the most recent developments in this field are examined, and the effectiveness of using neuropeptides in treating several inflammatory and autoimmune disorders is highlighted.
Notch signalling during peripheral T-cell activation and differentiation
Barbara A. Osborne and Lisa M. Minter
p64 | doi:10.1038/nri1998
Notch proteins are known to have crucial roles in determining cell fate during lymphoid development. But now, new research indicates that Notch signalling might also be important during T-cell activation and differentiation in the periphery, as discussed in this Review.
Perspective
Opinion
Identifying and hurdling obstacles to translational research
Ian Sabroe, David H. Dockrell, Stefanie N. Vogel, Stephen A. Renshaw, Moira K. B. Whyte and Steven K. Dower
p77 | doi:10.1038/nri1999
Translating basic research into viable therapies is challenged by many obstacles. In this Opinion article, Ian Sabroe and colleagues identify some of these obstacles and suggest a series of strategies to maximize the potential of translational research.
Correspondence
Correspondence: Interferons, immunity and cancer immunoediting leading to impaired immune function in cancer patients
Gerald Brandacher, Raimund Margreiter and Dietmar Fuchs
| doi:10.1038/nri1961-c1
